Nasdaq · CIK 0001847367
ALMS ALUMIS INC.
Insider trading from SEC Form 4. Last filing 33 d ago. Close $7.16 on Oct 9, 2026, +61% from the 52-week low and -76% from the high.
Last 90 days
Net insider value
+$9.7M
more bought than sold
Buys
1
$11M by 1 insider
Sells
1
$1.0M by 1 insider
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
ALMSOct 9, 2026 · close 7.16
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ALUMIS INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | Srinivas Akkaraju director buy | $11M 986,721 shares | +22% | - | |
| 40Moderate | Srinivas Akkaraju director sell | $1.0M 96,131 shares | -2% | - | |
| 66Notable | Srinivas Akkaraju director buy | $1.5M 320,290 shares | +10% | +29% from low-65% from high | |
| 42Moderate | Foresite Capital Management VI LLC owner buy | $202k 45,000 shares | +1% | +29% from low-65% from high | |
| 42Moderate | Foresite Labs, LLC owner buy | $202k 45,000 shares | +1% | +29% from low-65% from high | |
| 50Moderate | James B. Tananbaum director, owner buy | $202k 45,000 shares | +1% | +29% from low-65% from high | |
| 54Moderate | Martin Babler President, CEO and Chairman buy | $101k 15,650 shares | +17% | +103% from low-44% from high | |
| 50Moderate | Alan Colowick director buy | $130k 18,404 shares | - | +103% from low-44% from high |
Transactions
The last 34 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Srinivas Akkaraju director | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +220,070 | $11.17 | $2.5M | 4,711,801 | 33 d ago |
| Sep 4, 2026 | Srinivas Akkaraju director | POpen-market purchase Common Stockindirect: By Samsara Opportunity Fund, L.P. | +220,070 | $11.17 | $2.5M | 2,073,558 | 33 d ago |
| Sep 8, 2026 | Srinivas Akkaraju director | SOpen-market sale Common Stockindirect: By Samsara BioCapital, L.P. | -48,066 | $10.55 | $507k | 4,663,735 | 33 d ago |
| Sep 8, 2026 | Srinivas Akkaraju director | SOpen-market sale Common Stockindirect: By Samsara Opportunity Fund, L.P. | -48,065 | $10.55 | $507k | 2,025,493 | 33 d ago |
| Sep 8, 2026 | Srinivas Akkaraju director | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +273,291 | $10.63 | $2.9M | 4,937,026 | 33 d ago |
| Sep 8, 2026 | Srinivas Akkaraju director | POpen-market purchase Common Stockindirect: By Samsara Opportunity Fund, L.P. | +273,290 | $10.63 | $2.9M | 2,298,783 | 33 d ago |
| May 21, 2025 | Srinivas Akkaraju director | AGrant or award Common Stockindirect: By Samsara BioCapital, L.P. | +1,214,582 | - | - | 4,801,370 | May 23, 2025 |
| May 21, 2025 | AyurMaya Capital Management Company, LP director, owner, other | AGrant or award Common Stock, par value $0.0001 per share ("Common Stock")indirect: See footnotes | +4,493,741 | - | - | 15,139,707 | May 23, 2025 |
| May 21, 2025 | Patrick Machado director | AGrant or award Common Stockindirect: By Trust | +7,064 | - | - | 7,064 | May 23, 2025 |
| May 21, 2025 | Patrick Machado director | AGrant or award Stock Option (Right to Buy)derivative | +44,364 | - | - | 44,364 | May 23, 2025 |
| May 21, 2025 | Patrick Machado director | AGrant or award Stock Option (Right to Buy)derivative | +11,189 | - | - | 11,189 | May 23, 2025 |
| May 21, 2025 | Patrick Machado director | AGrant or award Stock Option (Right to Buy)derivative | +41,499 | - | - | 41,499 | May 23, 2025 |
| May 21, 2025 | Patrick Machado director | AGrant or award Stock Option (Right to Buy)derivative | +13,804 | - | - | 13,804 | May 23, 2025 |
| May 21, 2025 | Patrick Machado director | AGrant or award Stock Option (Right to Buy)derivative | +19,528 | - | - | 19,528 | May 23, 2025 |
| May 2, 2025 | James B. Tananbaum director, owner | POpen-market purchase Common Stockindirect: See Footnote | +25,000 | $4.62 | $116k | 4,227,670 | May 6, 2025 |
| May 2, 2025 | Foresite Labs, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +25,000 | $4.62 | $116k | 4,227,670 | May 6, 2025 |
| May 2, 2025 | Foresite Capital Management VI LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +25,000 | $4.62 | $116k | 4,227,670 | May 6, 2025 |
| May 2, 2025 | Srinivas Akkaraju director | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +159,920 | $4.55 | $728k | 3,426,418 | May 6, 2025 |
| May 5, 2025 | Srinivas Akkaraju director | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +138,368 | $4.58 | $634k | 3,564,786 | May 6, 2025 |
| May 6, 2025 | James B. Tananbaum director, owner | POpen-market purchase Common Stockindirect: See Footnote | +20,000 | $4.34 | $87k | 4,247,670 | May 6, 2025 |
| May 6, 2025 | Foresite Labs, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +20,000 | $4.34 | $87k | 4,247,670 | May 6, 2025 |
| May 6, 2025 | Foresite Capital Management VI LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +20,000 | $4.34 | $87k | 4,247,670 | May 6, 2025 |
| May 5, 2025 | Srinivas Akkaraju director | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +22,002 | $5.27 | $116k | 3,586,788 | May 6, 2025 |
| Apr 1, 2025 | Martin Babler President, CEO and Chairman | POpen-market purchase Common Stockindirect: By Trust | +15,650 | $6.44 | $101k | 106,454 | Apr 3, 2025 |
| Apr 1, 2025 | Alan Colowick director | POpen-market purchase Common Stockindirect: By Revocable Living Trust | +16,104 | $6.97 | $112k | 16,104 | Apr 3, 2025 |
| Apr 2, 2025 | Alan Colowick director | POpen-market purchase Common Stockindirect: By Revocable Living Trust | +2,300 | $7.49 | $17k | 18,404 | Apr 3, 2025 |
| Feb 18, 2025 | Martin Babler President, CEO and Chairman | AGrant or award Stock Option (Right to Buy)derivative | +523,000 | $0.00 | $0 | 523,000 | Feb 20, 2025 |
| Feb 18, 2025 | Jorn Drappa Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +180,000 | $0.00 | $0 | 180,000 | Feb 20, 2025 |
| Feb 18, 2025 | Sara Klein Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +180,000 | $0.00 | $0 | 180,000 | Feb 20, 2025 |
| Feb 18, 2025 | Mark Christopher Bradley Chief Development Officer | AGrant or award Stock Option (Right to Buy)derivative | +140,000 | $0.00 | $0 | 140,000 | Feb 20, 2025 |
| Feb 18, 2025 | John R. Schroer Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +140,000 | $0.00 | $0 | 140,000 | Feb 20, 2025 |
| Feb 18, 2025 | Derrick Richardson SVP, People and Culture | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Feb 20, 2025 |
| Feb 18, 2025 | Roy C. Hardiman Chief Business & Strategy Ofcr | AGrant or award Stock Option (Right to Buy)derivative | +140,000 | $0.00 | $0 | 140,000 | Feb 20, 2025 |
| Feb 18, 2025 | David M Goldstein Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +180,000 | $0.00 | $0 | 180,000 | Feb 20, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Srinivas Akkarajuowner, director
- AyurMaya Capital Management Company, LPdirector, owner, other
- Martin BablerPresident, CEO and Chairman
- Mark Christopher BradleyChief Development Officer
- Alan Colowickdirector
- Jorn DrappaChief Medical Officer
- Foresite Capital Management VI LLCowner
- Foresite Labs, LLCowner
- David M GoldsteinChief Scientific Officer
- Roy C. HardimanChief Business & Strategy Ofcr
- Sara KleinChief Legal Officer
- Patrick Machadodirector
- Derrick RichardsonSVP, People and Culture
- John R. SchroerChief Financial Officer
- James B. Tananbaumdirector, owner
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.